ChoLAB / Genome Editing Lab

We are committed to tackling the challenges that have hindered the full potential of gene editing. This includes exploring novel approaches and strategies to overcome existing limitations, aiming for solutions that have yet to be achieved in the field of gene correction. Through these efforts, we strive to develop more reliable and accurate tools for gene editing that can address previously unsolved issues. ex) In 2022, we developed the world’s first mitochondrial adenine base editor, TALED. This was a significant achievement because half of mitochondrial diseases can be corrected using adenine base editor. However, until then, no mitochondrial adenine base editor existed, and we recognized the need for such technology. In 2024, we developed an enhanced TALED that addresses off-target effects, further advancing the technology. Genome Editing for Major Diseases: We apply genome editing technologies to address significant human diseases, including cancer, neurodegenerative disorders, etc.